Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)
ID: 347227Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/347227

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-152.html
Timeline
    Description

    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Impacts of Climate Change Across the Cancer Control Continuum" (R21 Clinical Trial Optional). This initiative aims to support exploratory research that examines the effects of climate change on cancer risks and survivorship, as well as strategies to mitigate these impacts, emphasizing innovative and multidisciplinary approaches. Eligible applicants include a wide range of organizations such as educational institutions, non-profits, and government agencies, with funding available up to $275,000 over a two-year period. Applications are due by May 7, 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-152.html for more details.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-152-Full-Announcement.html
    PAR-23-152.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Cancer Institute (NCI), has issued a Notice of Funding Opportunity (NOFO) titled "Impacts of Climate Change Across the Cancer Control Continuum" (PAR-23-152). This initiative aims to support exploratory research examining how climate change affects cancer risks and survivorship, along with strategies to mitigate these impacts. Eligible organizations include educational institutions, non-profits, and government agencies, with funding up to $275,000 over two years, with applications due by specified dates from 2026. The research must incorporate collaboration with climate change experts and focus on innovative, multidisciplinary approaches to address issues such as environmental exposures, healthcare disruptions, and health equity influenced by climate dynamics. Applications will be evaluated based on significance, investigator qualifications, innovation, and approach, with additional emphasis on addressing barriers to cancer prevention related to climate challenges. The overarching goal is to deepen understanding of climate change's role in cancer while fostering new methodologies for improved health outcomes in vulnerable populations.
    Similar Opportunities
    Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)" aimed at fostering innovative research on the intersection of climate change and cancer. This R21 Exploratory/Developmental Research Grant seeks to explore various aspects of cancer risks exacerbated by climate change, including environmental influences, healthcare disruptions, and health disparities, with a focus on multidisciplinary approaches and collaboration with climate change experts. The grant supports studies with budgets up to $275,000 over a two-year period, and eligible applicants include higher education institutions, nonprofits, state and local governments, and for-profit organizations. Interested parties should note that the application deadline is May 7, 2026, and can find more information at the provided link or contact NIH Grants Information at grantsinfo@nih.gov.
    Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity focused on the impacts of climate change across the cancer control continuum, designated as the R01 Clinical Trial Optional grant. This initiative aims to support innovative research that assesses the effects of climate-related changes on cancer risks, prevention, survivorship, and healthcare delivery, with an emphasis on developing interventions to address health disparities and enhancing climate-resilient healthcare systems. The funding opportunity is critical for advancing understanding in this area and promoting multidisciplinary research to tackle significant challenges in cancer care exacerbated by environmental changes. Interested applicants, including higher education institutions, non-profits, and various government entities, must submit their applications by May 7, 2026, and can find additional details and guidelines at the provided NIH link or by contacting grantsinfo@nih.gov.
    Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)" aimed at researching the effects of climate change on cancer risk, prevention, and survivorship. This initiative encourages innovative studies that explore how environmental changes influence cancer risks and healthcare delivery, particularly focusing on health inequities among vulnerable populations. The funding supports a maximum project period of five years with no specified budget limit, and applications can be submitted starting January 5, 2025, with deadlines extending until February 2026. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Exploratory Grants in Cancer Control through the R21 Clinical Trial Optional mechanism, aimed at advancing innovative research in cancer control. This funding opportunity encourages applications focused on behavioral modification, screening, and understanding the etiological factors of cancer, with the goal of developing novel methodologies and tools that can significantly impact population-based cancer research. Grants of up to $275,000 are available for projects lasting up to two years, with application deadlines beginning January 16, 2025, and continuing through 2028. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PA-25-253.html.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)." This initiative encourages applications that propose innovative secondary data analyses and integration of existing datasets to address significant scientific questions related to cancer risk, prevention, and treatment outcomes. The program aims to leverage diverse data sources, including clinical, environmental, and genomic datasets, to enhance understanding of cancer and improve public health strategies. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofit organizations, and tribal governments, with a maximum funding amount of $200,000 and a project duration of up to two years. Interested parties can find more information and application details at the NIH grants website, with the submission deadline set for September 7, 2026.
    Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem," aimed at supporting research projects that enhance cancer communication strategies. The initiative focuses on three key areas: the application of new cancer communication surveillance methods, the development of rapid pilot interventions, and the creation of multilevel communication models that emphasize bidirectional influences in cancer prevention and control. This funding, available through R21 exploratory/developmental grants, provides up to $275,000 for a maximum of two years, with applications due starting January 16, 2025. Interested applicants can find more information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem," aimed at supporting exploratory research projects in cancer communication. This initiative focuses on three key areas: developing new cancer communication surveillance strategies, creating rapid intervention methods, and establishing multilevel communication models to enhance cancer prevention and control efforts. The NIH emphasizes the importance of utilizing contemporary methodologies, such as social media analysis and artificial intelligence, to address misinformation and improve health literacy in cancer care. Eligible applicants can receive funding of up to $275,000 for a maximum duration of two years, with applications due by September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or refer to the detailed announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-165.html.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity for secondary analysis and integration of existing datasets to elucidate cancer risk and related outcomes. This initiative encourages innovative research that leverages existing clinical, genomic, and epidemiological data to address critical questions in cancer control, with a focus on risk prediction, survival, and treatment responses. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and foreign entities, with a budget cap of $275,000 over a two-year period. Applications are due by September 7, 2026, and interested parties can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-255.html.